4.02
price up icon6.63%   0.25
after-market アフターアワーズ: 3.99 -0.03 -0.75%
loading
前日終値:
$3.77
開ける:
$3.74
24時間の取引高:
183.56K
Relative Volume:
1.54
時価総額:
$34.73M
収益:
$140.46M
当期純損益:
$-146.34M
株価収益率:
-3.1654
EPS:
-1.27
ネットキャッシュフロー:
$-117.73M
1週間 パフォーマンス:
+3.61%
1か月 パフォーマンス:
-11.65%
6か月 パフォーマンス:
-54.25%
1年 パフォーマンス:
-67.11%
1日の値動き範囲:
Value
$3.74
$4.1552
1週間の範囲:
Value
$3.6503
$4.35
52週間の値動き範囲:
Value
$3.51
$16.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1159)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
279
Name
Twitter
@Karyopharm
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

KPTI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
4.02 32.57M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
387.77 96.01B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
556.55 57.86B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
429.93 57.02B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
637.56 39.10B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.10 34.45B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-16 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-11 再開されました H.C. Wainwright Buy
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Aug 12, 2025

Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Karyopharm Therapeutics: Q2 Earnings Snapshot - Norwalk Hour

Aug 12, 2025
pulisher
Aug 12, 2025

Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - ca.finance.yahoo.com

Aug 12, 2025
pulisher
Aug 12, 2025

Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha

Aug 11, 2025
pulisher
Aug 11, 2025

Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2025
pulisher
Aug 11, 2025

Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com Nigeria

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView

Aug 11, 2025
pulisher
Aug 11, 2025

Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru

Aug 11, 2025
pulisher
Aug 09, 2025

Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace

Aug 09, 2025
pulisher
Aug 08, 2025

Earnings Outlook For Karyopharm Therapeutics - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

How moving averages guide Karyopharm Therapeutics Inc. tradingMarket Timing Strategy with Technical Filters - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Karyopharm Therapeutics shares rise 1.78% after-hours following Bicycle Therapeutics' board expansion. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 08, 2025

Tick level data insight on Karyopharm Therapeutics Inc. volatilityTechnical Trade Plan with Entry Checklist - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesFree Weekly Potential Breakout Stock List - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Aug 08, 2025
pulisher
Aug 07, 2025

What data driven models say about Karyopharm Therapeutics Inc.’s futureBuy Strategy Review With Performance Summary - Newser

Aug 07, 2025
pulisher
Aug 06, 2025

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 - Eastern Progress

Aug 06, 2025
pulisher
Aug 06, 2025

Karyopharm Therapeutics Inc. stock prediction for this weekAI Swing Strategy Signal Forecasting System - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Candlestick signals on Karyopharm Therapeutics Inc. stock todayHigh Reward Picks with Tight Risk Control - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Is a relief rally coming for Karyopharm Therapeutics Inc. holdersFast Entry Strategy with Price Prediction - Newser

Aug 05, 2025
pulisher
Aug 05, 2025

Karyopharm to Report Second Quarter 2025 Financial Results on Au - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

Will Karyopharm Therapeutics Inc. stock split in the near futureStock Price Prediction Using AI Tools - Newser

Aug 05, 2025
pulisher
Aug 04, 2025

Karyopharm Therapeutics Inc. Sees Spike in Bullish Option FlowPattern Alert With ROI Driven Strategy Shared - beatles.ru

Aug 04, 2025
pulisher
Aug 03, 2025

Is Karyopharm Therapeutics Inc. a growth stock or a value stockTriple-digit profit margins - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionUnlock real-time trading signals for gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Karyopharm Therapeutics Inc. stock price move sharplyUnlock powerful portfolio management tools - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Karyopharm Therapeutics Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Karyopharm Therapeutics Inc. stockBuild a winning portfolio with smart picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Will Karyopharm Therapeutics Inc. see short term momentumFree AI Screening for Swing Trade Picks - Newser

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Karyopharm Therapeutics Inc. stockFree Daily Trading Room Entry - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Should I hold or sell Karyopharm Therapeutics Inc. stock in 2025Overwhelming financial success - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

When is Karyopharm Therapeutics Inc. stock expected to show significant growthCapitalize on fast-moving stock opportunities - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress

Aug 02, 2025
pulisher
Aug 02, 2025

Is Karyopharm Therapeutics Inc. stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionEntry Signal Momentum Tracker Review - beatles.ru

Aug 02, 2025
pulisher
Aug 02, 2025

Karyopharm's Strategic Use of Inducement Grants to Attract Talent in a Competitive Biotech Landscape - AInvest

Aug 02, 2025

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$35.86
price down icon 0.91%
$81.61
price up icon 3.06%
$25.68
price down icon 9.08%
$122.00
price up icon 8.07%
$111.00
price up icon 1.59%
biotechnology ONC
$288.10
price down icon 0.57%
大文字化:     |  ボリューム (24 時間):